ArticleJournal of endocrinological investigation2026
Puerarin suppress adipogenesis and inflammation on orbital fibroblasts from patients with thyroid eye disease.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo investigate the therapeutic effects of puerarin in reducing adipogenesis and controlling inflammation in primary orbital fibroblasts derived from patients with thyroid eye disease (TED), and to explore the potential underlying mechanisms.
methodsAfter primary fibroblast culture and identification, the Cell Counting Kit-8 (CCK-8) was used to estimate the cytotoxic effects of puerarin. Wound-healing test was performed to assess the impact of puerarin on cellular migration. Adipogenic models were built with or without puerarin and inflammation model was built with the induction of IL-1β. Levels of IL-6, IL-8, CXCL-1, ADIPOQ, FABP4, and PPARγ were determined using quantitative real-time polymerase chain reaction (PCR). IL-6 and IL-8 in the cell supernatant were measured using enzyme-linked immunosorbent assay (ELISA). We performed network pharmacology and molecular docking to identify possible pathway and validated with Western blot.
resultsPuerarin significantly reduce the wound healing area and lipid area (p < 0.001, p = 0.004, p < 0.001 for 5µM, 10µM and 25µM, respectively) but no difference was found between the different puerarin groups. The levels of ADIPOQ, FABP4, and PPARγ were significantly decreased in the 5µM-puerarin treated group (p = 0.032, 0.041, 0.008, respectively), and the levels of IL-6 and IL-8 were significantly decreased in the puerarin-treated inflammation group (p < 0.01). PIK3CA and AKT 1 were identified as core targets, and the results were further supported by western blotting.
conclusionPuerarin has anti-adipogenic and anti-inflammatory effects on the fibroblasts of patients with TED. These effects may be mediated by the PI3K-AKT pathway. Puerarin may be a potential treatment option for TED.
Indexed as
Identifiers
41212406What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.